Moody National Bank Trust Division held its position in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,593 shares of the company’s stock at the close of the 2nd quarter. Moody National Bank Trust Division’s holdings in Eli Lilly and were worth $1,942,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Heritage Trust Co bought a new stake in Eli Lilly and in the 1st quarter worth about $135,000. Point72 Asia Hong Kong Ltd increased its holdings in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares in the last quarter. Cornerstone Advisors Inc. increased its holdings in Eli Lilly and by 18.4% in the 2nd quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after buying an additional 313 shares in the last quarter. Penserra Capital Management LLC increased its holdings in Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares in the last quarter. Finally, American National Bank increased its holdings in Eli Lilly and by 5.2% in the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after buying an additional 104 shares in the last quarter. Institutional investors own 75.77% of the company’s stock.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now directly owns 123,865,804 shares of the company’s stock, valued at $10,040,562,072.24. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 825,000 shares of company stock worth $68,456,650. 0.20% of the stock is owned by corporate insiders.
Several research firms recently commented on LLY. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Morgan Stanley reiterated a “hold” rating and issued a $86.00 price objective on shares of Eli Lilly and in a report on Friday. Sanford C. Bernstein reiterated an “outperform” rating and issued a $88.00 price objective on shares of Eli Lilly and in a report on Sunday, May 21st. TheStreet downgraded Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. Finally, BMO Capital Markets reiterated an “underperform” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and an average price target of $88.27.
Eli Lilly and Company (LLY) opened at 82.44 on Friday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market capitalization of $86.97 billion, a PE ratio of 35.67 and a beta of 0.34. The stock’s 50 day moving average price is $80.89 and its 200-day moving average price is $82.06.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the company earned $0.86 earnings per share. Eli Lilly and’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend was Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.
ILLEGAL ACTIVITY NOTICE: This article was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.chaffeybreeze.com/2017/09/16/eli-lilly-and-company-lly-holdings-held-by-moody-national-bank-trust-division.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.